

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1645 1631

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>JS</i>	AA	3,171,820	03/02/65	Volz et al.	521	61	02/17/64
<i>JS</i>	AB	5,223,409	06/29/93	Ladner et al.	435	69.7	03/01/91
<i>JS</i>	AC	6,013,478	01/11/00	Wells et al.	435	69.1	06/24/98
<i>JS</i>	AD	6,171,820	01/09/01	Short	435	69.1	02/04/99
<i>JS</i>	AE	2003/0224404	12/04/03	Vega et al.	435	6	02/24/03

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>JS</i>	AF	01/61344	08/23/01	PCT				
<i>JS</i>	AG	01/025438	04/12/01	PCT				
<i>JS</i>	AH	04/022747	03/18/04	PCT				
<i>JS</i>	AI	04/022593	03/18/04	PCT				
<i>JS</i>	AJ	0 240 224	10/07/87	EP				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
<i>JS</i>	AK	Kuhn "Structural basis for the positional specificity of lipxygenases" Prostaglandins and other lipid mediators 62(3):255-270 (2000)
<i>JS</i>	AL	Lewerenz et al. "Shared receptor components but distinct complexes for alpha and beta interferons" J. Mol. Biol. 282(3):585-599 (1998)
<i>JS</i>	AM	Manetti et al. "Design and realization of a tailor-made enzyme to modify the molecular recognition of 2-arylpropionic esters by Candida rugosa lipase" Biochem. Biophys. Acta 1543(1): 146-158 (2000)

Examiner Signature <i>JS</i>	Date Considered 4/26/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))	Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355
	Applicant Rene Gantier et al.	
	Filing Date September 8, 2003	Group Art Unit 1645

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4797368	01/10/89	Carter et al.	435	320	03/15/85
	AB	5139941	08/18/92	Muzyczka et al.	435	172.3	10/25/91
	AC	5571698	11/05/96	Ladner et al.	435	69.7	06/18/93
	AD	5723323	03/03/98	Kauffman et al.	435	172.3	12/02/94
	AE	5753500	05/19/98	Shenk et al.	435	320.1	04/03/95
	AF	5763239	06/09/98	Short et al.	435	172.1	06/18/96
	AG	5770434	06/23/98	Huse	435	252.33	05/15/95
	AH	5779434	07/14/98	De Long	415	104	02/06/97
	AI	5798390	08/25/98	Weber et al.	514	634	05/22/95
	AJ	5837500	11/17/98	Ladner et al.	435	69.7	04/03/95
	AK	5862514	01/19/99	Huse et al.	702	22	12/06/96
	AL	5871974	02/16/99	Huse	435	69.7	12/02/94
	AM	6001574	12/14/99	Short et al.	435	6	03/04/98
	AN	6057103	05/02/00	Short	435	6	08/26/97
	AO	6096548	08/01/00	Stemmer	435	440	02/03/97
	AP	6117679	09/12/00	Stemmer	435	440	05/25/96
	AQ	6127175	10/03/00	Vigne et al.	435	325	07/17/97
	AR	6132970	10/17/00	Stemmer	435	6	06/19/98
	AS	6156509	12/05/00	Schellenberger	435	6	11/12/97
	AT	6165793	12/26/00	Stemmer	435	440	05/08/98
	AU	6174673	01/16/01	Short et al.	435	6	06/16/98
	AV	6180406	01/30/01	Stemmer	435	440	06/17/98
	AW	6238884	05/29/01	Short et al.	435	69.1	03/09/99
	AX	6258530	07/10/01	Huse	435	6	12/30/94

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No



Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-013001 / 923		Application No. 10/658,355		
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Rene Gantier et al.				
				Filing Date September 8, 2003		Group Art Unit 1645 1631		
Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>PS</i>	AY	02/16606	02/28/02	PCT			X	
<i>PS</i>	AZ	99/11764	11/15/01	PCT				

3/11/1999

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
<i>PS</i>	BA	Altschul et al., "Basic Local Alignment Search Tool", J. Molec. Biol., 215:403-410 (1990)
	BB	Ashktorab et al., "Identification of Nuclear Proteins That Specifically Interact with Adeno-Associated Virus Type 2 Inverted Terminal Repeat Hairpin DNA", Journal of Virology, 63:3034-3039 (1989)
	BC	ATCC accession no. VR-1449, "Simian virus 15", (accessed on 09/05/2002)
	BD	ATCC accession no. VR-645, "Adeno-associated virus 1 deposited as Adeno-associated (satellite) virus type 1", (accessed on 09/05/2002)
	BE	ATCC accession no. VR-646, "Adeno-associated virus 4 deposited as Adeno-associated virus type 4", (accessed on 09/05/2002)
	BF	ATCC accession no. VR-680, "Adeno-associated virus 2 deposited as Adeno-associated virus type 2", (accessed on 09/05/2002)
	BG	ATCC accession no. VR-681, "Adeno-associated virus 3 deposited as Adeno-associated virus type 3", (accessed on 09/05/2002)
	BH	Atkinson et al., "A high-throughput hybridization method for titer determination of viruses and gene therapy vectors", Nucleic Acids Research, 26:2821-2823 (1998)
	BI	Batchu et al., "Disassociation of Conventional DNA Binding and Endonuclease Activities by an Adeno-Associated Virus Rep78 Mutant", Biochemical And Biophysical Research Communications, 210:717-725 (1995)
	BJ	Beaton et al., "Expression from the Adeno-Associated Virus p5 and p19 Promoters Is Negatively Regulated in trans by the rep Protein", Journal of Virology, 63:4450-4454 (1989)
	BK	Beck-Sickinger et al., "Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations", Eur. J. Biochem., 223:947-958 (1994)
	BL	Carrillo et al., "The Multiple Sequence Alignment Problem in Biology", SIAM J. Applied Math, 48:1073-1082 (1988)
	BM	Cassinotti et al., "Organization of the Adeno-Associated Virus (AAV) Capsid Gene: Mapping of a Minor Spliced mRNA Coding for Virus Capsid Protein 1", Virology, 167:176-184 (1988)
	BN	Certified English Translation of PCT Patent Application No. WO 01/86291, "Method for Determining the Titer of Biological Agents in Living Target Cells."
	BO	Certified English Translation of PCT Patent Application No. WO 02/16606, "Method for Massive Directed Mutagenesis."
<i>not supplied</i>	BP	Chadeuf et al., "Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome", J. Gene Med., 2:260-268 (2000)

Examiner Signature <i>Theresa 3</i>	Date Considered 9/30/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-013001 / 923		Application No. 10/658,355	
List of Patents and Publications for Applicant's Information Disclosure Statement				Applicant Rene Gantier et al.			
				Filing Date September 8, 2003		Group Art Unit 1645 1631	
				(37 CFR §1.98(b))			
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	BQ	Charbord <i>et al.</i> "Normal human granulo monocytic bone marrow progenitor cells responsiveness to colony stimulating activity" <i>Nouv. Rev. Fr. Hematol.</i> 22: 357-370, (1980)					
	BR	Chejanovsky <i>et al.</i> , "Mutagenesis of an AUG Codon in the Adeno-Associated Virus rep Gene: Effects on Viral DNA Replication", <i>J. Virology</i> , 173:120-128 (1989)					
	BS	Chejanovsky <i>et al.</i> , "Mutation of a Consensus Purine Nucleotide Binding Site in the Adeno-Associated Virus rep Gene Generates a Dominant Negative Phenotype for DNA Replication", <i>J. Virology</i> , 64:1764-1770 (1990)					
	BT	Cullen <i>et al.</i> , "Analysis of the Physical State of Different Human Papillomavirus DNAs in Intraepithelial and Invasive Cervical Neoplasm", <i>Journal of Virology</i> , 65:606-612 (1991)					
	BU	Davis <i>et al.</i> "High throughput method for creating and screening recombinant adenoviruses" <i>Gene Therapy</i> 5(8):1148-1152 (1998)					
	BV	Davis <i>et al.</i> , "Analysis of the Effects of Charge Cluster Mutations in Adeno-Associated Virus Rep68 Protein In Vitro", <i>Journal of Virology</i> , 73:2084-2093 (1999)					
	BW	Davis <i>et al.</i> , "Mutational Analysis of Adeno-Associated Virus Type 2 Rep68 Protein Endonuclease Activity on Partially Single-Stranded Substrates", <i>Journal of Virology</i> , 74:2936-2942 (2000)					
	BX	Deng <i>et al.</i> , "Site-Directed Mutagenesis of Virtually Any Plasmid by Eliminating a Unique Site", <i>Analytical Biochemistry</i> , 200:81-88 (1992)					
	BY	Derwent # 013914049, WPI Acc. No. 2001-398262/200142, for French Patent FR 2802645 and PCT Patent Application WO 2001/44809 "Evaluating the performance of complex biological agents in target cells, for selecting gene therapy vectors with optimal properties, comprises constructing a theoretical curve"					
	BZ	Derwent # 014262217, WPI Acc. No. 2002-082915/200211, for PCT Patent Application WO 2001/86291 A1, "Determining titer of biological agent, useful e.g. for gene therapy vectors or vaccines, is based on measuring reaction with cells at constant concentration, over a specified time period"					
	CA	Devereux <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX", <i>Nucleic Acids Research</i> , 12(1):387-395 (1984)					
	CB	Gavin <i>et al.</i> , "Charge-to-Alanine Mutagenesis of the Adeno-Associated Virus Type 2 Rep78/68 Proteins Yields Temperature-Sensitive and Magnesium-Dependent Variants", <i>Journal of Virology</i> , 73:9433-9445 (1999)					
	CC	Genbank accession no. NC_001401, Nucleotide, "Adeno-associated virus 2, complete genome", (accessed on 09/05/02)					
	CD	Genbank accession no. NC_001729, Nucleotide, "Adeno-associated virus 3, complete genome", (accessed on 09/05/02)					
	CE	Genbank accession no. NC_001829, Nucleotide, "Adeno-associated virus 4, complete genome", (accessed on 09/05/2002)					
	CF	Genbank accession no. NC_001863, Nucleotide, "Adeno-associated virus 3B, complete genome", (accessed on 09/05/2002)					
CG	Genbank accession no. NC_002077, Nucleotide, "Adeno-associated virus 1, complete genome", (accessed on 09/05/2002)						
CH	Gibbs <i>et al.</i> , "Rational Scanning Mutagenesis of a Protein Kinase Identifies Functional Regions Involved in Catalysis and Substrate Interactions", <i>Journal of Biology Chemistry</i> , 266:8923-8931 (1991)						
Examiner Signature 				Date Considered 4/30/06			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-013001 / 923		Application No. 10/658,355	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Rene Gantier et al.			
				Filing Date September 8, 2003		Group Art Unit 1645 1631	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
<i>RM</i>	CI	Gribskov et al., "Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins", Nucleic Acids Research, 14:6745-6763 (1986)					
	CJ	Hermonat et al., "Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants", Journal of Virology, 51:329-339 (1984)					
	CK	Hermonat, P.L., "Down-regulation of the human c-fos and c-myc proto-oncogene promoters by adeno-associated virus Rep78", Cancer Letters, 81:129-136 (1994)					
	CL	Hill A.V., "The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves", Proceedings of the Physiological, Journal of Physiology, 40:iv-vii (1910)					
	CM	Hill et al., "XLVII. The Combinations Of Haemoglobin With Oxygen And With Carbon Monoxide", I. Biochem. J., 7:471-480 (1913)					
	CN	Horer et al., "Mutational Analysis of Adeno-Associated Virus Rep Protein-Mediated Inhibition of Heterologous and Homologous Promoters", Journal of Virology, 69:5485-5496 (1995)					
<i>not supported</i>	CO	Im et al., "Partial Purification of Adeno-Associated Virus Rep78, Rep52, and Rep40 and Their Biochemical Characterization", Journal of Virology, 66:1119-1128 (1992)					
<i>RM</i>	CP	Im et al., "The AAV Origin Binding Protein Rep68 Is an ATP-Dependent Site-Specific Endonuclease with DNA Helicase Activity", Cell, 61:447-457 (1990)					
	CQ	Kechli et al., "Expression of the Human Immunodeficiency Virus Type 1 Primer Binding Sequence Inhibits HIV-1 Replication", Human Gene Therapy, 9:587-590 (1998)					
	CR	Kyostio et al., "Analysis of Adeno-Associated Virus (AAV) Wild-Type and Mutant Rep Proteins for Their Abilities To Negatively Regulate AAV p5 and p19 mRNA Levels", Journal of Virology, 68:2947-2957 (1994)					
	CS	Kyostio et al., "Identification of Mutant Adeno-Associated Virus Rep Proteins Which Are Dominant-Negative For DNA Helicase Activity", Biochemical and Biophysical Research Communications, 220:294-299 (1996)					
	CT	Kyostio et al., "Negative Regulation of the Adeno-Associated Virus (AAV) P5 Promoter Involves both the P5 Rep Binding Site and the Consensus ATP-Binding Motif of the AAV Rep68 Protein", Journal of Virology, 69:6787-6796 (1995)					
	CU	Marcello et al., "Adeno-Associated Virus Type 2 Rep Protein Inhibits Human Papillomavirus Type 16 E2 Recruitment of the Transcriptional Coactivator p300", Journal of Virology, 74:9090-9098 (2000)					
	CV	Matsushita et al., "Localization of von Willebrand Factor-binding Sites for Platelet Glycoprotein Ib and Biotin by Charged-to-Alanine Scanning Mutagenesis", Journal of Biology Chemistry, 275:11044-11049 (2000)					
	CW	McCarty et al., "Analysis of Mutations in Adeno-Associated Virus Rep Protein In Vivo and In Vitro", Journal of Virology, 66:4050-4057 (1992)					
	CX	Mendelson et al., "Identification of the trans-Acting Rep Proteins of Adeno-Associated Virus by Antibodies to a Synthetic Oligopeptide", Journal of Virology, 60:823-832 (1986)					
	CY	Mittereder et al., "Evaluation of the Concentration and Bioactivity of Adenovirus Vectors for Gene Therapy", Journal of Virology, 70:7498-7509 (1996)					
	CZ	Moullier et al., "Comparative binding of wheat germ agglutinin and its succinylated form on lymphocytes" <i>European J. Biochem.</i> 161:197-204 (1986)					
<i>✓</i>	DA	Needleman et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", Journal of Molec. Biol., 48:443-453 (1970)					
Examiner Signature <i>[Signature]</i>				Date Considered 4/30/06			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-013001 / 923		Application No. 10/658,355	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Rene Gantier et al.			
				Filing Date September 8, 2003		Group Art Unit 1645-1631	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
<i>RM</i>	DB	Nelson et al., "Characterization of Diverse Viral Vector Preparations, Using a Sample and Rapid Whole-Virion Dot-Blot Method", Hum. Gene Ther., 9:2401-2405 (1998)					
	DC	Ni et al., "In Vitro Replication of Adeno-Associated Virus DNA", Journal of Virology, 68:1128-1138 (1994)					
	DD	Owens et al., "Adeno-Associated Virus Rep Proteins Produced in Insect and Mammalian Expression Systems: Wild-Type and Dominant-Negative Mutant Proteins Bind to the Viral Replication Origin", Journal of Virology, 184:14-22 (1991)					
	DE	Owens et al., "Identification of a DNA-Binding Domain in the Amino Terminus of Adeno-Associated Virus Rep Proteins," J. Virology, 67(2):997-1005 (1993)					
	DF	Owens et al., "In Vitro Resolution of Adeno-Associated Virus DNA Hairpin Termini by Wild-Type Rep Protein Is Inhibited by a Dominant-Negative Mutant of Rep", Journal of Virology, 66:1236-1240 (1992)					
	DG	Pearson et al., "Improved tools for biological sequence comparison", Proc. Natl. Acad. Sci. USA, 85:2444-2448 (1988)					
	DH	Press Release 10; "Nautilus Biotech and Microbix Biosystems, Inc. (TSE: MBX) sign a distribution agreement for rAAV high-producer cells"; Paris- January 11, 2002; http://www.nautilusbiotech.com/news-pressrelease10.php3 , accessed on (2/28/02)					
	DI	Press Release 11; "Nautilus Biotech granted patent covering molecular fitness analysis with key applications in directed evolution and functional genomics target identification"; Paris- February 6, 2002; http://www.nautilusbiotech.com/news-pressrelease11.php3 , accessed on (2/28/02)					
	DJ	Press Release 6; "Nautilus Biotech S.A. Files a Key Patent Application in the U.S."; Paris- September 14, 2001; http://www.nautilusbiotech.com/news-pressrelease6.php3 , accessed on (2/28/02)					
	DK	Press Release 7; "Nautilus Biotech optimizes the AAV rep protein to increase rAAV productivity"; Paris- September 21, 2001; http://www.nautilusbiotech.com/news-pressrelease7.php3 , accessed on (2/28/02)					
	DL	Ropp et al., "Aequorea Green Fluorescent Protein Analysis by Flow Cytometry", Cytometry, 21:309-317 (1995)					
	DM	Ruffing et al., "Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif", J. Gen. Virol., 75:3385-3392 (1994)					
	DN	Ryan et al., "Sequence Requirements for Binding of Rep68 to the Adeno-Associated Virus Terminal Repeats", Journal of Virology, 70:1542-1553 (1996)					
	DO	Salvetti et al., "Factors Influencing Recombinant Adeno-Associated Virus Production", Hum. Gene Ther., 20:695-706 (1998)					
	DP	Samulski et al., "A Recombinant Plasmid from Which an Infectious Adeno-Associated Virus Genome Can Be Excised In Vitro and Its Use To Study Viral Replication", Journal of Virology, 61:3096-3101 (1987)					
	DQ	Schumann et al. "Intracellular Ca ²⁺ inhibits smooth muscle L-type Ca ²⁺ channels by activation of protein phosphatase type 2B and by direct interaction with the channel", J. General Physiology 110: 503-513, (1997)					
<i>Dr. Montide</i>	DR	Schwartz et al., "Matrices for Detecting Distant Relationships", Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358 (1978)					
<i>RM</i>	DS	Smith et al., "Comparison of Biosequences", Advances in Applied Mathematics, 2:482-489 (1981)					
Examiner Signature <i>Shane G.</i>				Date Considered 8/30/06			
EXAMINER: Initial if citation considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-013001 / 923		Application No. 10/658,355	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Rene Gantier et al.			
				Filing Date September 8, 2003		Group Art Unit 1645 631	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	DT	Srivastava et al., "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome", Journal of Virology, 45:555-564 (1983)					
	DU	Tessier et al., "Characterization of Adenovirus-Induced Inverted Terminal Repeat-Independent Amplification of Integrated Adeno-Associated Virus rep-cap Sequences", Journal of Virology, 75:375-383 (2001)					
	DV	Translation of PCT Patent Application WO 01/44809, "Methods for Screening or Assessing the Performance of a Collection of Biological Agents in Living Parget Cells, And Their Applications"					
	DW	Urabe et al., "Charged-to-Alanine Scanning Mutagenesis of the N-Terminal Half of Adeno-Associated Virus Type 2 Rep78 Protein", Journal of Virology, 23:2682-2693 (1999)					
	DX	Walker et al., "Mutational Analysis of the Adeno-Associated Virus Type 2 Rep68 Protein Helicase Motifs", Journal of Virology, 71:6996-7004 (1997)					
	DY	Walker et al., "Mutational Analysis of the Adeno-Associated Virus Rep68 Protein: Identification of Critical Residues Necessary for Site-Specific Endonuclease Activity", Journal of Virology, 71:2722-2730 (1997)					
	DZ	Watson et al., "Molecular Biology of the Gene", 4th Ed., The Benjamin/Cummings Pub. Co., p. 224, (1987)					
	EA	Weitzman et al., "Interaction of Wild-Type and Mutant Adeno-Associated Virus (AAV) Rep Proteins on AAV Hairpin DNA", Journal of Virology, 70:2240-2248 (1996)					
	EB	Weitzman et al., "Recruitment of Wild-Type and Recombinant Adeno-Associated Virus into Adenovirus Replication Centers", Journal of Virology, 70:1845-1854 (1996)					
	EC	Wu et al., "Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism", J. Virol., 74:8635-8647 (2000)					
	ED	Yang et al., "Analysis of the Terminal Repeat Binding Abilities of Mutant Adeno-Associated Virus Replication Proteins", Journal of Virology, 67: 4442-4447 (1993)					
	EE	Yang et al., "Mutational Analysis of the Adeno-Associated Virus rep Gene", Journal of Virology, 66:6058-6069 (1992)					
	EF	Yoon et al., "Amino-Terminal Domain Exchange Redirects Origin-Specific Interactions of Adeno-Associated Virus Rep78 In Vitro", Journal of Virology, 75:3230-3239 (2001)					


Examiner Signature 	Date Considered 8/20/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-013001 / 923		Application No. 10/658,355	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Rene Gantier et al.			
				Filing Date September 8, 2003		Group Art Unit 4645 1631	
U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
		none					

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>Jan</i>	AA	01/25253	04/12/01	PCT				
	AB	01/32844	05/10/01	PCT				
	AC	95/23813	09/08/95	PCT				
	AD	98/13487	04/02/98	PCT				
	AE	99/07833	02/18/99	PCT				
	AF	99/11764	03/11/99	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
		none

Examiner Signature <i>Michael G.</i>	Date Considered <i>4/26/06</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 1 of 1

Substitution Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>SG</i>	AA	5017371	05/21/91	Cummins	424	85.6	01/06/88
<i>J</i>	AB	5215741	06/01/93	Young et al.	424	85.7	10/30/90
<i>J</i>	AC	6036949	03/14/00	Richards et al.	424	85.7	03/05/98
<i>J</i>	AD	6506377	01/14/03	Cummins et al.	424	85.7	09/27/01

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
		none						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
		none

Examiner Signature <i>Paul G.</i>	Date Considered <i>4/27/06</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-013001 / 923	Application No. 10/658,355
	Applicant Rene Gantier et al.		
	Filing Date September 8, 2003	Group Art Unit 1631	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>LM</i>	AA	20020081574	6/27/2002	Collett et al.			
<i>LM</i>	AB	5925565	7/20/1999	Berlioz et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
		none						

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
		none

Examiner Signature <i>Rene Gantier</i>	Date Considered 4/26/08
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

3-17-04

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1644 1631	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

X+ Derwent English language abstract and/or English translation provided.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	0	1	2	9	2	0	3	07/10/03	Vega et al.	424	233.1	12/17/01
	B	0	1	2	9	5	8	4	07/10/03	Vega	435	5	12/13/00
	C	0	1	3	4	3	5	1	07/17/03	Vega et al.	435	69.1	12/17/01
	D	0	1	7	5	0	9	4	09/18/03	Vega	435	5	06/04/01
	E	0	2	2	4	4	0	4	12/04/03	Vega et al.	435	6	02/24/03
RM	F	4	0	4	4	1	2	6	08/23/77	Cook et al.	424	243	07/09/76
RM	G	4	3	6	4	9	2	3	12/21/82	Cook et al.	424	46	04/30/81
RM	H	4	4	1	4	2	0	9	11/08/83	Cook et al.	424	243	06/13/77
RM	I	4	5	2	2	8	1	1	06/11/85	Eppstein et al.	514	2	07/08/82

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
RM	J	0	1	3	2	7	1	1	A2 05/10/01	PCT				
	K	0	1	4	4	8	0	9	A2 06/21/01	PCT				X+
	L	0	1	8	6	2	9	1	A1 11/15/01	PCT				X+
	M	03	0	2	3	0	3	2	A2 03/20/03	PCT				
	N	03	0	1	8	8	2	0	A2 03/06/03	PCT				
	Ⓢ	1	0	2	2	3	3	5	07/26/00	EP				

EXAMINER

Handwritten signature

DATE CONSIDERED

4/30/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS SCANNING

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1644 1631	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

X+ Derwent English language abstract and/or English translation provided.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	P	2	8	0	2	6	4	5	A1 06/22/01	FR				X+
	Q	2	8	0	8	8	0	4	A1 11/16/01	FR				X+
<i>RM</i>	R	9	7	3	8	7	2	3	10/23/97	PCT				
<i>↓</i>	S	9	8	3	2	8	8	0	07/30/98	PCT				
<i>↓</i>	T	9	8	3	2	8	9	0	07/30/98	PCT				

X+ = An English Language Equivalent is provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>RM</i>	U	Astwood et al., "Stability of food allergens to digestion in vitro", <i>Nature Biotechnology</i> , 14:1269-1273 (1996)
<i>↓</i>	V	Bellido et al., "The phospholipid and fatty acid composition of skeletal muscle cells during culture in the presence of vitamin D-3 metabolites," <i>Biochim Biophys Acta</i> , 922(2):162-169 (1987)
	W	Bernkop-Schnurch, A. "The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins", <i>Journal of Controlled Release</i> , 52:1-16 (1998)
	X	Biron et al., "Natural Killer Cells In Antiviral Defenses: Function and Regulation by Innate Cytokines," <i>Annu. Rev. Immunol.</i> , 17:189-220 (1999)
	Y	Boger et al., "Surface Probability Profiles. A Heuristic Approach to the Selection of Synthetic Peptide Antigens," <i>Reports of the Sixth International Congress in Immunology</i> , p. 250 (1986)
<i>↓</i>	Z	Briand et al., "Impact of the lysine-188 and aspartic acid-189 inversion on activity of trypsin," <i>FEBS Lett.</i> , 442(1):43-47 (1999)

EXAMINER *Handwritten Signature*

DATE CONSIDERED

4/30/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS SCANNING













FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1044 1031	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

X+ Derwent English language abstract and/or English translation provided.


OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Cockburn, A. "Assuring the safety of genetically modified (GM) foods: the importance of an holistic, integrative approach", <i>Journal of Biotechnology</i> , <u>98</u> :79-106 (2002)
	AB	Dayhoff et al., "A Model of Evolutionary Change in Proteins," <i>Atlas of Protein Sequence and Structure</i> , <u>5</u> (3):345-352 (1978)
	AC	Diaz et al., "Nomenclature of the Human Interferon Genes," <i>J. Interferon Cytokine Res.</i> , <u>16</u> :179-180 (1996)
	AD	Drittanti et al., "Effects of 1,25-dihydroxyvitamin D-3 on phospholipid metabolism in chick myoblasts, <i>Biochim Biophys Acta.</i> , <u>962</u> (1):1-7 (1988)
	AE	Drittanti et al., "Changes in muscle lipid metabolism induced in vitro by 1,25-dihydroxy-vitamin D-3, <i>Biochim Biophys Acta</i> , <u>918</u> (1):83-92 (1987)
	AF	Drittanti et al., "Involvement of the 3',5'-cyclic AMP pathway in the induction of calmodulin synthesis in myoblasts by 1,25(OH)2-vitamin D3," <i>Biochim Biophys Res Commun.</i> , <u>192</u> (2):886-892 (1993)
	AG	Drittanti et al., "Modulation of DNA synthesis in cultured muscle cells by 1,25-dihydroxyvitamin D-3," <i>Biochim Biophys Acta.</i> , <u>1014</u> (2):112-119 (1989)
	AH	Drittanti et al., "Stimulation of calmodulin synthesis in proliferating myoblasts by 1,25-dihydroxy-vitamin D3," <i>Mol Cell Endocrinol.</i> , <u>74</u> (2):143-153 (1990)
	AI	Drittanti et al., "Optimised helper virus-free production of high-quality adeno-associated virus vectors," <i>J Gene Med.</i> , <u>3</u> (1):59-71 (2001)
	AJ	Drittanti et al., "Cystic fibrosis: gene therapy or preventive gene transfer?" <i>Gene Ther.</i> , <u>4</u> (10):1001-1003 (1997)
	AK	Drittanti et al., "High throughput production, screening and analysis of adeno-associated viral vectors," <i>Gene Ther.</i> , <u>7</u> (11):924-929 (2000)
	AL	Du et al., "Efficient transduction of human neurons with an adeno-associated virus vector," <i>Gene Ther</i> <u>3</u> :254-261 (1996)

EXAMINER



DATE CONSIDERED



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS SCANNING**












FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1644 1631	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

X+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Feng <i>et al.</i> , "Aligning Amino Acid Sequences: Comparison of Commonly Used Methods," <i>J. Mol. Evol.</i> , <u>21</u> :112-125 (1985)
	AN	Fitch, "An Improved Method of Testing for Evolutionary Homology," <i>J. Mol. Evol.</i> , <u>16</u> (1):9-16 (1966)
	AO	Fuchs, R.L. and J.D. Astwood, "Allergenicity Assessment of Foods Derived from Genetically Modified Plants", <i>Food Technology</i> , <u>50</u> :83-88 (1996)
	AP	Gantier <i>et al.</i> , "The L392V mutation of presenilin 1 associated with autosomal dominant early-onset Alzheimer's disease alters the secondary structure of the hydrophilic loop," <i>Neuroreport</i> , <u>10</u> (14):3071-3074 (1999)
	AQ	Gantier <i>et al.</i> , "The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta," <i>Neurosci Lett.</i> , <u>283</u> (3):217-220 (2000)
	AR	Gibrat <i>et al.</i> , "Surprising similarities in structure comparison," <i>Current Opinion in Structural Biology</i> , <u>6</u> :377-385 (1995)
	AS	Gonnet <i>et al.</i> , "Exhaustive Matching of the Entire Protein Sequence Database," <i>Science</i> , <u>256</u> :1433-1445 (1992)
	AT	Grantham, "Amino Acid Difference Formula to Help Explain Protein Evolution," <i>Science</i> , <u>185</u> :862-864 (1974)
	AU	Guyon <i>et al.</i> , "Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction," <i>J Clin Invest.</i> , <u>94</u> (1):16-24 (1994)
	AV	Guyon <i>et al.</i> , "Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss," <i>J Clin Invest.</i> , <u>102</u> (1):249-263 (1998)
	AW	Henikoff <i>et al.</i> , "Amino acid substitution matrices from protein blocks," <i>Proc. Natl. Acad. Sci. USA</i> , <u>89</u> :10915-10919 (1992)

EXAMINER

DATE CONSIDERED

4/27/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS SCANNING**












FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 4644 1631	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

X+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AX	Hibbert <i>et al.</i> , "Human Type 1 Interferons Differ Greatly in Their Effects on the Proliferation of Primary B Cells," <i>J. Interferon Cytokine Res.</i> , <u>19</u> :309-318 (1999)
	AY	Hoedemaekers <i>et al.</i> , "Differential susceptibility of young and old rat neuromuscular junctions to antibody-mediated AChR degradation in experimental autoimmune myasthenia gravis," <i>Ann N Y Acad Sci.</i> , <u>841</u> :550-554 (1998)
	AZ	Hoedemaekers <i>et al.</i> , "Role of target organ in determining susceptibility to experimental autoimmune myasthenia gravis," <i>J Neuroimmunol.</i> , <u>89</u> (1-2):131-141 (1998)
	BA	Holm <i>et al.</i> , "Mapping the Protein Universe," <i>Science</i> , <u>273</u> :595-602 (1996)
	BB	IUPAC-IUB "Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)," <i>Biochem.</i> , <u>11</u> :942-944 (1972)
	BC	IUPAC-IUB "Commission on Biochemical Nomenclature A One-Letter Notation for Amino Acid Sequences Tentative Rules", <i>J. Biol. Chem.</i> , <u>243</u> (13):3557-3559 (1968)
	BD	Johnson <i>et al.</i> , "A Structural Basis for Sequence Comparisons. An Evaluation of Scoring Methodologies," <i>J. Mol. Biol.</i> , <u>233</u> :716-738 (1993)
	BE	Jones <i>et al.</i> , "The rapid generation of mutation data matrices from protein sequences," <i>Comput. Appl. Biosci.</i> , <u>8</u> :275-282 (1992)
	BF	Lu, G., "TOP: a new method for protein structure comparisons and similarity searches," <i>J. Appl. Cryst.</i> , <u>33</u> :176-189 (2000)
	BG	Marrack <i>et al.</i> , "Type I Interferons Keep Activated T Cells Alive," <i>J. Exp. Med.</i> , <u>189</u> :521-530 (1999)
	BH	Masciovecchio <i>et al.</i> , "The interactivity between the CFTR gene and cystic fibrosis would be limited to the initial phase of the disease," <i>Genet Med.</i> , <u>2</u> (2):124-130 (2000)

EXAMINER



DATE CONSIDERED

9/27/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS
SCANNING













FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 4644 1631	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

X+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BI	McLachlan, "Tests for Comparing Related Amino-acid Sequences. Cytochrome c and Cytochrome c ₅₅₁ ," <i>J. Mol. Biol.</i> , <u>61</u> :409-424 (1971)
	BJ	Miyata, "Two Types of Amino Acid Substitutions in Protein Evolution," <i>J. Mol. Evol.</i> , <u>12</u> :219-236 (1979)
	BK	Morikawa <i>et al.</i> , "Recombinant interferon- α , - β and - γ enhance the proliferative response of human B cells," <i>J. Immunol.</i> , <u>139</u> :761-766 (1987)
	BL	Moulian <i>et al.</i> , "Respective role of thymus and muscle in autoimmune myasthenia gravis," <i>Ann N Y Acad Sci.</i> , <u>841</u> :397-406 (1998)
	BM	Murzin <i>et al.</i> , "SCOP: A Structural Classification of Proteins Database for the Investigation of Sequences and Structures," <i>J. Mol. Biol.</i> , <u>247</u> :536-540 (1995)
	BN	NCBI Nucleotide No. J00207
	BO	Orengo <i>et al.</i> , "CATH - a hierarchic classification of protein domain structures," <i>Structure</i> , <u>5(8)</u> :1093-1108 (1997)
	BP	Pestka, <i>et al.</i> , "Interferons and Their Actions," <i>Annu. Rev. Biochem.</i> , <u>56</u> :727-777 (1987)
	BQ	Piehler <i>et al.</i> , "New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface," <i>J. Biol. Chem.</i> , <u>275</u> :40425-40433 (2000)
	BR	Poëa <i>et al.</i> , "Modulation of acetylcholine receptor expression in seronegative myasthenia gravis," <i>Ann Neurol.</i> , <u>48(5)</u> :696-705 (2000)
	BS	Poëa <i>et al.</i> , "Expression of ciliary neurotrophic factor receptor in myasthenia gravis," <i>J Neuroimmunol.</i> , <u>120(1-2)</u> :180-189 (2001)
	BT	Rao, "New scoring matrix for amino acid residue exchanges based on residue characteristic physical parameters," <i>J. Pept. Protein Res.</i> , <u>29</u> :276-281 (1987)

EXAMINER



DATE CONSIDERED

4/27/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS SCANNING**












FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1644 1637	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

X+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BU	Raux <i>et al.</i> , "The -2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit," <i>Mol Psychiatry</i> , <u>7(9)</u> :1006-1011 (2002)
	BV	Raux <i>et al.</i> , "A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer's disease," <i>Human Mutat.</i> , Report #134, two pages (2000)
	BW	Raux <i>et al.</i> , "Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation," <i>Neurol.</i> , <u>55(10)</u> :1577-1578 (2000)
	BX	Risler <i>et al.</i> , "Amino Acid Substitutions in Structurally Related Proteins A Pattern Recognition Approach," <i>J. Mol. Biol.</i> , <u>204</u> :1019-1029 (1988)
	BY	Robert <i>et al.</i> , "Interferon Induces Proliferation In Leukemic And Normal B-Cell Subsets," <i>Hematol. Oncol.</i> , <u>4</u> :113-120 (1986)
	BZ	Roisman <i>et al.</i> , "Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking," <i>Proc. Natl. Acad. Sci. USA</i> , <u>98</u> :13231-13236 (2001)
	CA	Sali <i>et al.</i> , "Definition of General Topological Equivalence in Protein Structures," <i>J. Mol. Biol.</i> , <u>212</u> :403-428 (1990)
	CB	Sanchez <i>et al.</i> , "Spastic paraplegia and primary adrenal insufficiency: a case of adrenomyeloneuropathy," <i>Medicina (B Aires)</i> , <u>48(3)</u> :290-296 (1988) (Summary in English) <i>Summary ok</i>
	CC	Scheel-Toeller <i>et al.</i> , "Inhibition of T cell apoptosis by IFN- β rapidly reverses nuclear translocation of protein kinase C- δ ," <i>Eur. J. Immunol.</i> , <u>29</u> :2603-2612 (1999)
	CD	Shindyalov <i>et al.</i> , "Protein structure alignment by incremental combinatorial extension (CE) of the optimal path," <i>Protein Engineering</i> , <u>11(9)</u> :739-747 (1998)
	CE	Smith <i>et al.</i> , "Single-step purification of polypeptides expressed in <i>Escherichia coli</i> as fusions with glutathione S-transferase," <i>Gene</i> , <u>67</u> :31-40 (1988)

EXAMINER



DATE CONSIDERED

4/26/08

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS**
SCANNING




FORM PTO-1449	ATTY. DOCKET NO. 37851-923	SERIAL NO. 10/658,355	CONFIRM NO. 3519
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1644 1631	

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).


** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

X+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CF	Stark <i>et al.</i> , "How cells Respond to Interferons," <i>Annu. Rev. Biochem.</i> , <u>67</u> :227-264 (1998)
	CG	Wakkach <i>et al.</i> , "Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis", <i>J Immunol.</i> , <u>157</u> (8):3752-3760 (1996)
	CH	Woodley, J.F. "Enzymatic Barriers for GI Peptide and Protein Delivery", <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 11(2&3):61-95 (1994)

EXAMINER



DATE CONSIDERED

4/27/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: RATIONAL DIRECTED PROTEIN EVOLUTION USING TWO-DIMENSIONAL RATIONAL MUTAGENESIS SCANNING